Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-24T10:37:12.263Z Has data issue: false hasContentIssue false

13 - Evidence-based pharmacotherapy of Alzheimer's disease

Published online by Cambridge University Press:  05 August 2012

By
Darren Cotterell  and
Martin Brown
Edited by
Dan Stein ,
Bernard Lerer  and
Stephen M. Stahl
Dan Stein
Affiliation:
University of Cape Town
Bernard Lerer
Affiliation:
Hadassah-Hebrew Medical Centre
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Alzheimer's disease (AD) is increasingly being recognized as a huge worldwide challenge for health and social care organizations, particularly associated with demographic changes in population. This chapter describes the medications currently available to treat AD, and critically reviews the available evidence for their use. Four agents are licensed for the treatment of AD in both Europe and the USA: donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl) and memantine (Ebixa). The pharmacological premise underlying the development of these drugs is derived from the cholinergic hypothesis of AD suggesting that enhancement of levels of acetylcholine, through inhibition of degradation of the existing neurotransmitter, should provide symptomatic relief. Behavioral and psychological symptoms of dementia (BPSD) constitute a spectrum of non-cognitive symptoms found in AD, and include agitation and aggression, psychotic symptoms, mood disorders, disrupted sleep patterns, and behavioral disturbances.

Keywords

monoamine oxidase inhibitorspharmacotherapyphenelzineserotonin norepinephrine reuptake inhibitorssocial anxiety disorderreversible inhibitors of monoamine oxidase-Aselective serotonin reuptake inhibitors
Type
Chapter
Information
Essential Evidence-Based Psychopharmacology , pp. 262 - 277
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×